LX2931 is one of four programs in human clinical trials as part of Lexicon’s 10TO10 program. Initial results from this single ascending-dose trial in healthy volunteers demonstrated a potent, dose-dependent reduction in circulating lymphocytes, suggesting that the target of LX2931 may represent a new mechanism for regulating the immune response.
Philip Brown, senior vice president of clinical development at Lexicon, said: “We are encouraged not only by the rapid onset of action, but also by the timely recovery of lymphocyte counts as the drug candidate is cleared from the system. Based on these results, we are actively pursuing a multidose trial with LX2931.”